Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model
- PMID: 1515641
Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model
Abstract
Platelet aggregation plays an important role in the pathogenesis in arterial thrombotic disorders. The binding of fibrinogen via the Arg-Gly-Asp (RGD) recognition sequence to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor is an essential step of platelet aggregation induced by various physiologic agonists, and RGD-containing peptides that bind to the GPIIb/IIIa receptor inhibit thrombus formation in vivo. L-cysteine, N-(mercaptoacetyl)D-tyrosyl-L-arginylglycyl-L alpha-aspartyl-cyclic (1----5)-sulfide, 5-oxide (G4120), a cyclic RGD-containing synthetic pentapeptide, inhibits adenosine diphosphate (ADP)-induced platelet aggregation with 50% inhibition (IC50) at a concentration of 0.05 microgram/mL in human plasma, 0.12 microgram/mL in hamster plasma, and 11 micrograms/mL in rat plasma. Corresponding values for the linear tetrapeptide Arg-Gly-Asp-Phe (RGDF) were 7 and 100 micrograms/mL in human and hamster plasma. The antithrombotic effects of G4120 and RGDF were evaluated in a hamster model consisting of a mural platelet-rich femoral vein thrombus induced by standardized endothelial cell damage. Bolus intravenous injection of G4120 was followed by a biphasic disappearance of G4120 from plasma with t1/2 alpha of 3.7 minutes and t1/2 beta of 63 minutes, corresponding to a plasma clearance of 5.2 +/- 0.68 mL/min. Bolus intravenous injection of G4120 inhibited ex vivo platelet aggregation with 0.5 mumol/L ADP and in vivo thrombus formation in a dose-dependent manner, with ID50 of 11 and 11 micrograms/kg, respectively. Bolus injection of RGDF inhibited in vivo thrombus formation; 43% inhibition was obtained at a dose of 30 mg/kg. Thus, this hamster platelet-rich femoral vein thrombosis model may be useful for the investigation of the antithrombotic properties of platelet GPIIb/IIIa antagonistic peptides. The cyclic synthetic peptide G4120 appears to have a very potent antithrombotic activity in vivo.
Similar articles
-
Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.Thromb Haemost. 1994 Jan;71(1):95-102. Thromb Haemost. 1994. PMID: 8165652
-
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.Thromb Haemost. 1992 Sep 7;68(3):336-40. Thromb Haemost. 1992. PMID: 1440501
-
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.Arterioscler Thromb. 1993 May;13(5):738-47. doi: 10.1161/01.atv.13.5.738. Arterioscler Thromb. 1993. PMID: 8485125
-
Novel antithrombotic drugs in development.Drugs. 1995 Jun;49(6):856-84. doi: 10.2165/00003495-199549060-00002. Drugs. 1995. PMID: 7641602 Review.
-
[A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide].Orv Hetil. 1995 Jan 15;136(3):129-33. Orv Hetil. 1995. PMID: 7870410 Review. Hungarian.
Cited by
-
Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library.J Cell Biol. 1994 Feb;124(3):373-80. doi: 10.1083/jcb.124.3.373. J Cell Biol. 1994. PMID: 7507494 Free PMC article.
-
A novel targeted multi-functional fusion protein possesses inhibitory activities against bacteria, thrombin and platelet aggregation.Protein J. 2011 Dec;30(8):521-8. doi: 10.1007/s10930-011-9357-6. Protein J. 2011. PMID: 21959792
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical